Lakefront Biotherapeutics (GLPGF) EBT Margin (2014 - 2026)
Lakefront Biotherapeutics' (GLPGF) quarterly EBT Margin came in at 358.92% in Q2 2026, down 59888.0% year-over-year from N/an in Q2 2025, and down 266.68% quarter-over-quarter from 215.34% in Q1 2026.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EBT Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported EBT Margin for 13 consecutive years, with 358.92% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBT Margin fell 59888.0% year-over-year to 358.92% in Q2 2026; TTM through Jun 2026 was 30360.99%, a 3126554.0% increase from a year earlier, with the FY2025 full-year figure at 27050.71%, up 2816989.0% from the prior year.
- EBT Margin was 358.92% for Q2 2026 at Lakefront Biotherapeutics, down from 215.34% in the prior quarter.
- Over five years, EBT Margin peaked at 41940.1% in Q4 2022 and troughed at 8167.69% in Q4 2024.
- A 5-year average of 3727.29% and a median of 22.86% in 2023 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin surged 4194505 bps in 2022 and plunged 4091461 bps in 2023, its largest moves.
- Over 5 years, EBT Margin stood at 41940.1% in 2022, then slumped by 98 bps to 1025.49% in 2023, then tumbled by 896 bps to 8167.69% in 2024, then soared by 510 bps to 33453.14% in 2025, then slumped by 101 bps to 358.92% in 2026.
- The last three EBT Margin figures came in at 358.92% (Q2 2026), 215.34% (Q1 2026), and 33453.14% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | -20,427.46% |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -358.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -358.92% |
| Mar 31, 2026 | 215.34% |
| Dec 31, 2025 | 33,453.14% |
| Sep 30, 2025 | -678.61% |
| Jun 30, 2025 | 239.96% |
| Mar 31, 2025 | -208.55% |
| Dec 31, 2024 | -8,167.69% |
| Sep 30, 2024 | -57.26% |
| Jun 30, 2024 | -191.84% |
| Mar 31, 2024 | 36.74% |
| Dec 31, 2023 | 1,025.49% |
| Sep 30, 2023 | -23.23% |
| Jun 30, 2023 | -22.49% |
| Mar 31, 2023 | -19.43% |
| Dec 31, 2022 | 41,940.10% |
| Sep 30, 2022 | -27.58% |
| Jun 30, 2022 | -55.47% |
| Mar 31, 2022 | -8.50% |
| Dec 31, 2021 | -4.95% |
| Sep 30, 2021 | -55.27% |